These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 21840057)

  • 21. Can calcium chemoprevention of adenoma recurrence substitute or serve as an adjunct for colonoscopic surveillance?
    Shaukat A; Parekh M; Lipscomb J; Ladabaum U
    Int J Technol Assess Health Care; 2009 Apr; 25(2):222-31. PubMed ID: 19331713
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Very-low-dose aspirin and surveillance colonoscopy is cost-effective in secondary prevention of colorectal cancer in individuals with advanced adenomas: network meta-analysis and cost-effectiveness analysis.
    Veettil SK; Kew ST; Lim KG; Phisalprapa P; Kumar S; Lee YY; Chaiyakunapruk N
    BMC Gastroenterol; 2021 Mar; 21(1):130. PubMed ID: 33743605
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A further piece of the puzzle: positive FOBT, colonoscopy, aspirin and the prevention of colorectal cancer.
    Ockenga J
    Digestion; 2012; 85(4):276-7. PubMed ID: 22538259
    [No Abstract]   [Full Text] [Related]  

  • 24. Cost-effectiveness and budget impact analysis of a population-based screening program for colorectal cancer.
    Pil L; Fobelets M; Putman K; Trybou J; Annemans L
    Eur J Intern Med; 2016 Jul; 32():72-8. PubMed ID: 27157827
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Costs and effects of various analgesic treatments for patients with rheumatoid arthritis and osteoarthritis in the Netherlands.
    Al MJ; Maniadakis N; Grijseels EW; Janssen M
    Value Health; 2008; 11(4):589-99. PubMed ID: 18194404
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Health benefits and cost-effectiveness of a hybrid screening strategy for colorectal cancer.
    Dinh T; Ladabaum U; Alperin P; Caldwell C; Smith R; Levin TR
    Clin Gastroenterol Hepatol; 2013 Sep; 11(9):1158-66. PubMed ID: 23542330
    [TBL] [Abstract][Full Text] [Related]  

  • 27. COX-2 active agents in the chemoprevention of colorectal cancer.
    Kraus S; Naumov I; Arber N
    Recent Results Cancer Res; 2013; 191():95-103. PubMed ID: 22893201
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost-effectiveness of duloxetine in chronic low back pain: a Quebec societal perspective.
    Wielage R; Bansal M; Wilson K; Klein R; Happich M
    Spine (Phila Pa 1976); 2013 May; 38(11):936-46. PubMed ID: 23250234
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-utility analysis and economic burden of knee osteoarthritis treatment: the analysis from the real clinical practice.
    Turajane T; Chaweevanakorn U; Sungkhun P; Larbphiboonpong V; Wongbunnak R
    J Med Assoc Thai; 2012 Oct; 95 Suppl 10():S98-104. PubMed ID: 23451446
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Economic outcomes for celecoxib: a systematic review of pharmacoeconomic studies.
    Huelin R; Pokora T; Foster TS; Mould JF
    Expert Rev Pharmacoecon Outcomes Res; 2012 Aug; 12(4):505-23. PubMed ID: 22971036
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Patient preferences for the chemoprevention of esophageal adenocarcinoma in Barrett's esophagus.
    Hur C; Broughton DE; Ozanne E; Yachimski P; Nishioka NS; Gazelle GS
    Am J Gastroenterol; 2008 Oct; 103(10):2432-42. PubMed ID: 18775019
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chemoprevention of colorectal cancer: slow, steady progress.
    Burke CA; Bauer WM; Lashner B
    Cleve Clin J Med; 2003 Apr; 70(4):346-50. PubMed ID: 12701989
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Colorectal cancer chemoprevention: is this the future of colorectal cancer prevention?
    Manzano A; Pérez-Segura P
    ScientificWorldJournal; 2012; 2012():327341. PubMed ID: 22649288
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combinational chemoprevention effect of celecoxib and an oral antiangiogenic LHD4 on colorectal carcinogenesis in mice.
    Kim JY; Alam F; Chung SW; Park J; Jeon OC; Kim SY; Son WC; Byun Y
    Anticancer Drugs; 2014 Oct; 25(9):1061-71. PubMed ID: 25003253
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gene expression analysis proposes alternative pathways for the mechanism by which celecoxib selectively inhibits the growth of transformed but not normal enterocytes.
    Sagiv E; Rozovski U; Kazanov D; Liberman E; Arber N
    Clin Cancer Res; 2007 Nov; 13(22 Pt 1):6807-15. PubMed ID: 18006783
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost-effectiveness modeling of colorectal cancer: computed tomography colonography vs colonoscopy or fecal occult blood tests.
    Lucidarme O; Cadi M; Berger G; Taieb J; Poynard T; Grenier P; Beresniak A
    Eur J Radiol; 2012 Jul; 81(7):1413-9. PubMed ID: 21444171
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reappraisal of the options for colorectal cancer screening in England.
    Whyte S; Chilcott J; Halloran S
    Colorectal Dis; 2012 Sep; 14(9):e547-61. PubMed ID: 22390210
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost-effectiveness of apixaban compared with aspirin for stroke prevention in atrial fibrillation among patients unsuitable for warfarin.
    Lee S; Anglade MW; Meng J; Hagstrom K; Kluger J; Coleman CI
    Circ Cardiovasc Qual Outcomes; 2012 Jul; 5(4):472-9. PubMed ID: 22740012
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost-effectiveness of treatment strategies for osteoarthritis of the knee in Taiwan.
    Yen ZS; Lai MS; Wang CT; Chen LS; Chen SC; Chen WJ; Hou SM
    J Rheumatol; 2004 Sep; 31(9):1797-803. PubMed ID: 15338503
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Chemoprevention of colorectal cancer by aspirin: a cost-effectiveness analysis.
    Suleiman S; Rex DK; Sonnenberg A
    Gastroenterology; 2002 Jan; 122(1):78-84. PubMed ID: 11781283
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.